RxDoctor Payments Data

Paul Tolerico, MD

Interventional Cardiology · York, PANPI 1487692331

Payments from drug & device makers

What this record shows

18 manufacturers reported payments, led by Medtronic at 33.9% of the total. Reporting peaked in 2022 at $2,381 and has fallen 86.5% since, to $323 in 2025. That places this record below the midpoint for interventional cardiology clinicians in PA, where the typical reported total is $6,486.

$6,989in general payments, 2019–2025

Across 106 payments — averaging $65.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Cardiovascular Systems Inc.$2K
  • Boston Scientific$822
  • Abiomed$794
  • Edwards Lifesciences$299
  • Asahi Intecc USA, Inc.$214
  • plus $928 from 12 others
$125,058in research payments, 2019–2025

Across 85 payments — averaging $1471.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$40K
  • Inari Medical, Inc.$24K
  • Edwards Lifesciences$22K
  • Trireme Medical LLC$18K
  • Boston Scientific$14K
  • Biotronik Inc.$9K

What the payments were for

  • Travel & lodging$3,14145%
  • Food & beverage$3,84855%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,989 in reported general payments places this provider in the 50th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$178,593
Medicare patients
441
Services billed
1,042

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate18$88

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in York

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →